BioGalen Pharmaceuticals

Artemether & Lumefantrine Tablets

Anti-Malarial · Tablets / Dispersible Tablets · 20/120mg, 40/240mg, 80/480mg

WhatsApp Enquiry

Trade Information

Minimum Order Qty 10,000 tablets
Capacity 100 Million Tablets per month
Strength 20/120mg, 40/240mg, 80/480mg
Private Labelling Custom branding, artwork & market-specific labelling
Lead Time 45–60 days from order confirmation
Payment Terms LC at sight, TT (advance / against documents)
Shipping FOB / CIF to major international ports including Mombasa, Dar es Salaam, Lagos, Douala, Maputo
Pharmacopoeia BP, USP, IP compliant
Artemether & Lumefantrine Tablets 20/120mg, 40/240mg, 80/480mg - BioGalen Pharmaceuticals

Packing Options

  • Blister (Alu-Alu / Alu-PVC)
  • Strip pack
  • Hospital pack
  • Age-specific colour-coded packs
  • Custom packing as per buyer requirement

Regulatory & Quality

Registration Status Registered in multiple African markets. Dossier available for new market registration.
Regulatory Dossiers CTD / ACTD format dossiers available for submission to national drug authorities.
Stability Data Zone IVa & IVb stability data available (tropical climate conditions, 30°C/65% RH & 30°C/75% RH)
WHO Prequalification WHO-GMP Certified

Product Details

Composition Artemether + Lumefantrine
Dosage Form Tablets / Dispersible Tablets
Pack Size 1x6, 1x12, 1x18, 1x24 / Custom packing available
Storage Store below 30°C in a dry place, protected from light and moisture
Shelf Life 24 months from date of manufacture

Description

Artemether-Lumefantrine is a fixed-dose combination antimalarial medicine recommended by the World Health Organization (WHO) as a first-line treatment for uncomplicated Plasmodium falciparum malaria. It is one of the most widely used Artemisinin-based Combination Therapies (ACTs) globally.

BioGalen manufactures Artemether & Lumefantrine Tablets in three strength combinations (20/120mg, 40/240mg, 80/480mg) in both standard and dispersible tablet formulations. The dispersible variants are specifically designed for paediatric use, ensuring accurate dosing and improved compliance in children.

Our AL tablets are a critical product for malaria-endemic regions across Sub-Saharan Africa, Southeast Asia, and Latin America. They are widely procured through government tender programmes, NGO health initiatives, and private sector distribution channels.

Indications

  • Treatment of uncomplicated Plasmodium falciparum malaria
  • Mixed malarial infections involving P. falciparum
  • WHO-recommended first-line ACT therapy
  • Suitable for adults and children (dispersible tablets for paediatric use)

Available Variants

  • Artemether 20mg & Lumefantrine 120mg Tablets
  • Artemether 20mg & Lumefantrine 120mg Dispersible Tablets
  • Artemether 40mg & Lumefantrine 240mg Tablets
  • Artemether 40mg & Lumefantrine 240mg Dispersible Tablets
  • Artemether 80mg & Lumefantrine 480mg Tablets
  • Artemether 80mg & Lumefantrine 480mg Dispersible Tablets

Interested in Artemether & Lumefantrine Tablets?

Get competitive pricing for bulk orders, private labelling, and contract manufacturing.